Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that’s showing ...

Pope Francis woke up Tuesday to good news from his doctors: They upgraded his prognosis and say he is no longer in imminent ...

BILLERICA — Billerica Memorial High School has announced its honor roll for the second term of the 2024-2025 school year.

Uncertainty around President Donald Trump’s tariff policies have sent the major averages on a roller-coaster ride and spurred ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Overseas, Lilly is spending $1.8 billion to expand the production capacity at two plants in Ireland. Lilly also has a $2.5 billion plant under construction in Alzey, Germany, which is expected to ...

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...